相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
K. Tamura et al.
ANNALS OF ONCOLOGY (2017)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2017)
Pattern of metastatic spread and subcategories of breast cancer
Catharina Bartmann et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2017)
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
J. A. Mestres et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells
Sandeep Pallerla et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer A Randomized Clinical Trial
Hope S. Rugo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
Ander Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
Riccardo Soffietti et al.
NEURO-ONCOLOGY (2017)
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Sibylle Loibl et al.
ONCOLOGIST (2017)
Development of New ADC Technology with Topoisomerase I Inhibitor
Toshinori Agatsuma
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2017)
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
Rinath Jeselsohn et al.
CURRENT ONCOLOGY REPORTS (2017)
HSP90 proteins in the scenario of tumor complexity
Andrea Rasola
ONCOTARGET (2017)
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study
Gong Yue et al.
SCIENTIFIC REPORTS (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Direct estrogen receptor (ER)/HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER plus breast cancer
Denis Collins et al.
PLOS ONE (2017)
Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer
Xinmei Kang et al.
SCIENTIFIC REPORTS (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2017)
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
John M. Lambert et al.
ADVANCES IN THERAPY (2017)
Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: Overall survival results from BOLERO-1
D. Yardley et al.
CANCER RESEARCH (2017)
SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancer
H. S. Rugo et al.
CANCER RESEARCH (2017)
Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
G. Arpino et al.
CANCER RESEARCH (2017)
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
BREAST (2017)
Improved survival in metastatic breast cancer 1985-2016
Marie Sundquist et al.
BREAST (2017)
Treatment challenges and survival analysis of human epidermal growth factor receptor 2-positive breast cancer in real world
Praveen Adusumilli et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2017)
A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense et al.
BMC CANCER (2016)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer
Kathy Miller et al.
BMC CANCER (2016)
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel
Noelia Martinez-Janez et al.
BREAST CARE (2016)
Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer
S. Jain et al.
CANCER RESEARCH (2016)
Everolimus plus trastuzumab and vinorelbine for trastuzumabresistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3
C. Isaacs et al.
CANCER RESEARCH (2016)
Targeted Therapies for Brain Metastases from Breast Cancer
Vyshak Alva Venur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Brain metastasis in breast cancer: a comprehensive literature review
Rezvan Rostami et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Lessons from breast cancer trials of HER2-kinase inhibitors
Ian E. Krop
LANCET ONCOLOGY (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Nadia Harbeck et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome
Patrizia Vici et al.
ONCOTARGET (2016)
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
Arlene Chan
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
Laurence Lousberg et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial
Ahmad Awada et al.
JAMA ONCOLOGY (2016)
Efficacy results of a phase lb study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases.
Virginia F. Borges et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Ian E. Krop et al.
BREAST CANCER RESEARCH (2016)
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Edith A. Perez et al.
BREAST CANCER RESEARCH (2016)
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015
Cornelia Liedtke et al.
BREAST CARE (2015)
A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
Donald A. Bergstrom et al.
CANCER RESEARCH (2015)
SEOM clinical guidelines in metastatic breast cancer 2015
J. Gavila et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
Use of bevacizumab as a first-line treatment for metastatic breast cancer
L. Manso et al.
CURRENT ONCOLOGY (2015)
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers
C. Jackisch et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2015)
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Xavier Pivot et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
Karen A. Gelmon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Victoria Shang Wu et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
Aki Morikawa et al.
NEURO-ONCOLOGY (2015)
Breast cancer brain metastases: the last frontier
Jose Pablo Leone et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2015)
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer
Iason T. Papademetriou et al.
THERAPEUTIC DELIVERY (2015)
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
Diogo Mendes et al.
BREAST CANCER RESEARCH (2015)
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
S. M. Swain et al.
ANNALS OF ONCOLOGY (2014)
Metastatic breast cancer subtypes and central nervous system metastases
C. Aversa et al.
BREAST (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers
Mary L. Disis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
Komal Jhaveri et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Julie C. Friedland et al.
INVESTIGATIONAL NEW DRUGS (2014)
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Meng Zhao et al.
INVESTIGATIONAL NEW DRUGS (2014)
Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
Elham Fakhrejahani et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Naren Ramakrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
John M. Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
Naoki Hayashi et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
Shanu Modi et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Mario Giuliano et al.
BREAST CARE (2013)
Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
D. J. Slamon et al.
CANCER RESEARCH (2013)
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+advanced breast cancer
Miguel Martin et al.
EUROPEAN JOURNAL OF CANCER (2013)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer
Zhongzhen Guan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Cyclin D1 Determines Estrogen Signaling in the Mammary Gland In Vivo
Mathew C. Casimiro et al.
MOLECULAR ENDOCRINOLOGY (2013)
Control of cell cycle transcription during G1 and S phases
Cosetta Bertoli et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Breast cancer brain metastases: new directions in systemic therapy
Nancy U. Lin
ECANCERMEDICALSCIENCE (2013)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
J. Huober et al.
BREAST (2012)
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
Leticia De Mattos-Arruda et al.
ONCOLOGIST (2012)
PERTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER
M. B. Smith et al.
DRUGS OF TODAY (2012)
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Paul Hamberg et al.
CLINICAL BREAST CANCER (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
Gunter von Minckwitz et al.
EUROPEAN JOURNAL OF CANCER (2011)
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Vicente Valero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Michael Andersson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
Kenichi Inoue et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Systemic treatment in breast-cancer patients with brain metastasis
Cagatay Arslan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Andrew M. Wardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
S. Chandarlapaty et al.
ONCOGENE (2010)
Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
David Cameron et al.
ONCOLOGIST (2010)
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor-Positive Metastatic Breast Cancer
Lee S. Schwarzberg et al.
ONCOLOGIST (2010)
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
Y. H. Park et al.
BRITISH JOURNAL OF CANCER (2009)
Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance
Jing Lu et al.
CLINICAL CANCER RESEARCH (2009)
Interaction of antibodies with ErbB receptor extracellular regions
Karl R. Schmitz et al.
EXPERIMENTAL CELL RESEARCH (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
Julien J. M. Boone et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer
Karen Bullock et al.
ONCOLOGIST (2008)
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Aleix Prat et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer
Rupert Bartsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Central nervous system metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab:: Incidence, survival, and risk factors
Stefania Gori et al.
ONCOLOGIST (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
DA Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
RMB Loureiro et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
GE Konecny et al.
CLINICAL CANCER RESEARCH (2004)
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
AJ Clayton et al.
BRITISH JOURNAL OF CANCER (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
Cyclin D1, EMS1 and 11q13 amplification in breast cancer
CJ Ormandy et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
J Liang et al.
NATURE MEDICINE (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Specific protection against breast cancers by cyclin D1 ablation
QY Yu et al.
NATURE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
